

—

Notice of extraordinary General meeting of SenzaGen AB

The shareholders of SenzaGen AB, reg. no. 556821-9207, (the “Company”) are hereby summoned to the extraordinary general meeting on Friday 7 September 2018 at 08.00 at Medicon Village, building 401 Länken 2, Scheelevägen 2 in Lund.

Right to attend the general meeting and notification

Shareholders who wish to attend the extraordinary general meeting must be included in the share register maintained by Euroclear Sweden AB on the record date, which is Saturday 1 September 2018, (since the record day occurs on a Saturday a shareholder must be registered in the share register maintained by Euroclear Sweden AB no later than on 31 August 2018).

Shareholders shall also to notify the Company of their participation and any assistants (no more than two) in the extraordinary general meeting no later than Monday 3 September 2018. The notification shall be in writing to SenzaGen, Medicon Village, building 401, 223 81 Lund or via e-mail: anmalan@senzagen.com. The notification should state the name, personal/corporate identity number, shareholding, address and telephone number and, when applicable, information about representatives, counsels and assistants. When applicable, complete authorization documents, such as registration certificates and powers of attorney for representatives and assistants, should be appended the notification.

Nominee shares

Shareholders, whose shares are registered in the name of a bank or other nominee, must temporarily register their shares in their own name with Euroclear Sweden AB in order to be entitled to participate in the general meeting. Such registration, which normally is processed in a few days, must be completed no later than 31 August 2018 and must therefore be requested from the nominee well before this date.

Proxy etc.

Shareholders represented by proxy shall issue dated and signed power of attorney for the proxy. If the proxy is issued by a legal entity, attested copies of the certificate of registration or equivalent authorization documents, evidencing the authority to issue the proxy, shall be enclosed. The proxy's validity may not be more than five years from the issuance. A copy of the proxy in original and, where applicable, the registration certificate, should be submitted to the Company by mail at the address set forth above well in advance of the extraordinary general meeting. The proxy in original and, when applicable, the certificate of registration must be presented at the extraordinary general meeting. A form proxy will be available for downloading on the Company's website www.senzagen.com.

Proposed agenda

1. Election of chairman of the meeting.
2. Preparation and approval of voting list.

SENZAGEN AB

MEDICON VILLAGE,
SCHEELEVÄGEN 2
223 81 LUND, SWEDEN

P: +46 46 2756200
W: WWW.SENZAGEN.COM
E: INFO@SENZAGEN.COM

3. Election of one or two persons to certify the minutes.
4. Question whether the general meeting has been duly convened.
5. Approval of the agenda.
6. Election of new director of the board.
7. Closing of the meeting.

Proposed resolutions

Item 1: Election of chairman of the meeting

The board of directors proposes that Carl Borrebaeck is elected as chairman of the general meeting.

Item Fel! Hittar inte referenskälla.: Election of new director of the board

It is proposed that the board of directors shall comprise of five directors.

It is further proposed that the remuneration to the director proposed for election shall be SEK 100,000. The total remuneration for the board of directors will amount to SEK 600,000 in accordance with the remuneration resolved on by the annual general meeting.

It is proposed to elect Peter Nählstedt as new director. The directors Carl Borrebaeck (chairman), Ann Gidner, Ian Kimber and Laura Chirica remain as directors.

Further information regarding the proposed director

Peter Nählstedt

Education and background

Peter Nählstedt holds a M.Sc. in engineering and a Bachelor's degree in Business administration. Peter was previously CEO of Probi AB and chairman of the board of International Probiotics Association Europe. He has also held several positions within GE Healthcare Life Sciences, such as general manager of BioProcess North America, and as director of South America Trelleborg Marine Systems.

Current Assignments: None

Year of birth: 1974

Nationality: Swedish

Direct or related person ownership in the Company: 0

Number of shares and votes

The total number of shares in the Company as of the date hereof amounts to 15,559,250 shares, with a corresponding number of votes. The Company holds no own shares.

Documents

The complete proposals are included in this notice. The notice and proxy forms are available at the Company at Medicon Village, building 401 in Lund and at the Company's website

SENZAGEN AB

MEDICON VILLAGE,
SCHEELEVÄGEN 2
223 81 LUND, SWEDEN

P: +46 46 2756200
W: WWW.SENZAGEN.COM
E: INFO@SENZAGEN.COM

—
www.senzagen.com, at least two (2) weeks in advance of the extraordinary general meeting. All documents will be sent to shareholders who request it and provide their e-mail or postal address.

The shareholders hereby notified regarding the right to, at the extraordinary general meeting, request information from the board of directors and managing director according to Ch. 7 § 32 of the Swedish Companies Act.

Lund in August 2018
SenzaGen AB
The Board of Directors

For more information, please contact:

Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

About GARD™

GARD™ is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen

SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in

This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above at August 22, 2018, at 09.30.

SenzaGen AB are listed on Nasdaq First North in Stockholm and FNCA is the company's Certified Adviser. For more information, please visit www.senzagen.com